Healthcare Sales & Marketing Network News: cathepsin K

Searching News Database: cathepsin K

HSMN NewsFeed - 2 Sep 2016
Merck Provides Update on Odanacatib Development Program
Biopharmaceuticals

HSMN NewsFeed - 13 May 2010
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jun 2008
Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2007
Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals

Return to NewsFeed

Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 2 additional stories matching:
cathepsin K
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.